Literature DB >> 22209738

Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML.

Rajesh R Nair1, Joel H Tolentino, Raul F Argilagos, Ling Zhang, Javier Pinilla-Ibarz, Lori A Hazlehurst.   

Abstract

In this study, we show that conditioned media (CM) generated from bone marrow (BM)-derived mesenchymal stromal cells lead to BCR-ABL independent STAT3 activation. Activation of STAT3 is important not only for survival of CML cells but also for its protection against Nilotinib (NI), within the BM microenvironment. Reducing the expression of both JAK2 and TYK2 or utilizing a pan-JAK inhibitor blocked CM-mediated STAT3 activation and sensitized CML cells to NI-mediated cell death. Finally, we demonstrate that in patient-derived primitive leukemic cells, co-cultured with BM stromal cells, inhibition of BCR-ABL and JAK activity was a successful strategy to potentiate their elimination.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209738      PMCID: PMC3331955          DOI: 10.1016/j.leukres.2011.12.002

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  27 in total

1.  Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.

Authors:  Philippe Rousselot; Francoise Huguet; Delphine Rea; Laurence Legros; Jean Michel Cayuela; Odile Maarek; Odile Blanchet; Gerald Marit; Eliane Gluckman; Josy Reiffers; Martine Gardembas; François-Xavier Mahon
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

Review 2.  Evaluating the effect of P210 BCR/ABL on growth of hematopoietic progenitor cells and its role in the pathogenesis of human chronic myelogenous leukemia.

Authors:  M L Gishizky; J Johnson-White; O N Witte
Journal:  Semin Hematol       Date:  1993-07       Impact factor: 3.851

3.  Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.

Authors:  Melissa S Holtz; Marilyn L Slovak; Feiyu Zhang; Charles L Sawyers; Stephen J Forman; Ravi Bhatia
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

4.  Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.

Authors:  Karl J Aichberger; Matthias Mayerhofer; Maria-Theresa Krauth; Hans Skvara; Stefan Florian; Karoline Sonneck; Cahit Akgul; Sophia Derdak; Winfried F Pickl; Volker Wacheck; Edgar Selzer; Brett P Monia; Richard Moriggl; Peter Valent; Christian Sillaber
Journal:  Blood       Date:  2004-12-30       Impact factor: 22.113

5.  BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.

Authors:  Su Chu; Melissa Holtz; Mamta Gupta; Ravi Bhatia
Journal:  Blood       Date:  2003-12-11       Impact factor: 22.113

6.  Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

Authors:  Hagop Kantarjian; Ricardo Pasquini; Vincent Lévy; Saengsuree Jootar; Jerzy Holowiecki; Nelson Hamerschlak; Timothy Hughes; Eric Bleickardt; David Dejardin; Jorge Cortes; Neil P Shah
Journal:  Cancer       Date:  2009-09-15       Impact factor: 6.860

7.  Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.

Authors:  Hagop M Kantarjian; Andreas Hochhaus; Giuseppe Saglio; Carmino De Souza; Ian W Flinn; Leif Stenke; Yeow-Tee Goh; Gianantonio Rosti; Hirohisa Nakamae; Neil J Gallagher; Albert Hoenekopp; Rick E Blakesley; Richard A Larson; Timothy P Hughes
Journal:  Lancet Oncol       Date:  2011-08-17       Impact factor: 41.316

8.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

Authors:  Hagop Kantarjian; Francis Giles; Lydia Wunderle; Kapil Bhalla; Susan O'Brien; Barbara Wassmann; Chiaki Tanaka; Paul Manley; Patricia Rae; William Mietlowski; Kathy Bochinski; Andreas Hochhaus; James D Griffin; Dieter Hoelzer; Maher Albitar; Margaret Dugan; Jorge Cortes; Leila Alland; Oliver G Ottmann
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

9.  The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells.

Authors:  F Belloc; K Airiau; M Jeanneteau; M Garcia; E Guérin; E Lippert; F Moreau-Gaudry; F-X Mahon
Journal:  Leukemia       Date:  2009-01-22       Impact factor: 11.528

10.  Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.

Authors:  Nadine N Bewry; Rajesh R Nair; Michael F Emmons; David Boulware; Javier Pinilla-Ibarz; Lori A Hazlehurst
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

View more
  14 in total

Review 1.  Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Authors:  Tariq I Mughal; Saulius Girnius; Steven T Rosen; Shaji Kumar; Adrian Wiestner; Omar Abdel-Wahab; Jean-Jacques Kiladjian; Wyndham H Wilson; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-02-17

Review 2.  Pushing the limits of targeted therapy in chronic myeloid leukaemia.

Authors:  Thomas O'Hare; Matthew S Zabriskie; Anna M Eiring; Michael W Deininger
Journal:  Nat Rev Cancer       Date:  2012-07-24       Impact factor: 60.716

3.  BCR-ABL1-positive microvesicles malignantly transform human bone marrow mesenchymal stem cells in vitro.

Authors:  Fen-Fen Fu; Xiao-Jian Zhu; Hong-Xiang Wang; Li-Ming Zhang; Guo-Lin Yuan; Zhi-Chao Chen; Qiu-Bai Li
Journal:  Acta Pharmacol Sin       Date:  2017-08-24       Impact factor: 6.150

4.  Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.

Authors:  Bin Zhang; Min Li; Tinisha McDonald; Tessa L Holyoake; Randall T Moon; Dario Campana; Leonard Shultz; Ravi Bhatia
Journal:  Blood       Date:  2013-01-08       Impact factor: 22.113

Review 5.  Cancer prevention and therapy through the modulation of the tumor microenvironment.

Authors:  Stephanie C Casey; Amedeo Amedei; Katia Aquilano; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan E Bilsland; Chandra S Boosani; Sophie Chen; Maria Rosa Ciriolo; Sarah Crawford; Hiromasa Fujii; Alexandros G Georgakilas; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Kanya Honoki; W Nicol Keith; Sid P Kerkar; Sulma I Mohammed; Elena Niccolai; Somaira Nowsheen; H P Vasantha Rupasinghe; Abbas Samadi; Neetu Singh; Wamidh H Talib; Vasundara Venkateswaran; Richard L Whelan; Xujuan Yang; Dean W Felsher
Journal:  Semin Cancer Biol       Date:  2015-04-10       Impact factor: 15.707

Review 6.  Contribution of the bone marrow stromal cells in mediating drug resistance in hematopoietic tumors.

Authors:  Wei-Chih Chen; Gangqing Hu; Lori A Hazlehurst
Journal:  Curr Opin Pharmacol       Date:  2020-09-06       Impact factor: 5.547

7.  Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI.

Authors:  Puneet Agarwal; Bin Zhang; Yinwei Ho; Amy Cook; Ling Li; Fady M Mikhail; Youzhen Wang; Margaret E McLaughlin; Ravi Bhatia
Journal:  Blood       Date:  2016-12-23       Impact factor: 22.113

8.  What challenges remain in chronic myeloid leukemia research?

Authors:  Angelo M Carella; Susan Branford; Michael Deininger; Francois X Mahon; Giuseppe Saglio; Anna Eiring; Jamshid Khorashad; Thomas O'Hare; John M Goldman
Journal:  Haematologica       Date:  2013-08       Impact factor: 9.941

9.  JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.

Authors:  Paolo Gallipoli; Amy Cook; Susan Rhodes; Lisa Hopcroft; Helen Wheadon; Anthony D Whetton; Heather G Jørgensen; Ravi Bhatia; Tessa L Holyoake
Journal:  Blood       Date:  2014-06-23       Impact factor: 22.113

10.  A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease.

Authors:  Kendra Sweet; Lori Hazlehurst; Eva Sahakian; John Powers; Lisa Nodzon; Fadi Kayali; Kelly Hyland; Ashley Nelson; Javier Pinilla-Ibarz
Journal:  Leuk Res       Date:  2018-10-09       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.